Department of Radiology, Center for Medical Imaging, and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No.17 People's South Road, Chengdu, 610041, China.
Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
Adv Mater. 2020 Apr;32(13):e1902604. doi: 10.1002/adma.201902604. Epub 2019 Jul 28.
Development of drug-delivery systems that selectively target neoplastic cells has been a major goal of nanomedicine. One major strategy for achieving this milestone is to install ligands on the surface of nanocarriers to enhance delivery to target tissues, as well as to enhance internalization of nanocarriers by target cells, which improves accuracy, efficacy, and ultimately enhances patient outcomes. Herein, recent advances regarding the development of ligand-installed nanocarriers are introduced and the effect of their design on biological performance is discussed. Besides academic achievements, progress on ligand-installed nanocarriers in clinical trials is presented, along with the challenges faced by these formulations. Lastly, the future perspectives of ligand-installed nanocarriers are discussed, with particular emphasis on their potential for emerging precision therapies.
开发能够选择性靶向肿瘤细胞的药物输送系统一直是纳米医学的主要目标之一。实现这一里程碑的一个主要策略是在纳米载体表面安装配体,以增强向靶组织的输送,以及增强靶细胞对纳米载体的内化,从而提高准确性、疗效,并最终改善患者的治疗效果。本文介绍了近年来在配体修饰的纳米载体的发展方面的进展,并讨论了它们的设计对生物性能的影响。除了学术成就,还介绍了配体修饰的纳米载体在临床试验中的进展,以及这些制剂所面临的挑战。最后,讨论了配体修饰的纳米载体的未来前景,特别强调了它们在新兴精准治疗中的潜力。